ProQR Therapeutics (NASDAQ:PRQR) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note released on Tuesday morning, Marketbeat reports. The firm issued an overweight rating and a $8.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for ProQR Therapeutics’ FY2025 earnings at ($0.39) EPS.

PRQR has been the subject of several other reports. Evercore ISI began coverage on ProQR Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $5.00 price target for the company. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Monday, March 10th. Oppenheimer began coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target for the company. HC Wainwright boosted their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, March 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.75.

ProQR Therapeutics Stock Up 3.6 %

NASDAQ PRQR opened at $1.72 on Tuesday. The firm’s 50 day moving average is $1.56 and its 200-day moving average is $2.49. The company has a market capitalization of $180.97 million, a PE ratio of -5.38 and a beta of 0.25. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors have recently modified their holdings of the business. Affinity Asset Advisors LLC acquired a new stake in ProQR Therapeutics in the 4th quarter worth about $7,486,000. M&T Bank Corp bought a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $330,000. Altium Capital Management LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $1,524,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of ProQR Therapeutics by 164.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company’s stock valued at $25,446,000 after buying an additional 5,976,813 shares during the period. Finally, XTX Topco Ltd acquired a new stake in ProQR Therapeutics during the fourth quarter worth approximately $163,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).